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ABSTRACT 1 
The Warburg effect in tumour cells is associated with the upregulation of glycolysis to 2 
generate ATP, even under normoxic conditions and the presence of fully functioning 3 
mitochondria. However, scientific advances made over the past 15 years have reformed this 4 
perspective, demonstrating the importance of oxidative phosphorylation (OXPHOS) as well as 5 
glycolysis in malignant cells. The metabolic phenotypes in melanoma display heterogeneic 6 
dynamism (metabolic plasticity) between glycolysis and OXPHOS, conferring a survival 7 
advantage to adapt to harsh conditions and pathways of chemoresistance. Furthermore, the 8 
simultaneous upregulation of both OXPHOS and glycolysis (metabolic symbiosis) has been 9 
shown to be vital for melanoma progression. The tumour microenvironment (TME) has an 10 
essential supporting role in promoting progression, invasion and metastasis of melanoma. 11 
Mesenchymal stromal cells (MSCs) in the TME show a symbiotic relationship with melanoma, 12 
protecting tumour cells from apoptosis and conferring chemoresistance. With the significant 13 
role of OXPHOS in metabolic plasticity and symbiosis, our review outlines how mitochondrial 14 
transfer from MSCs to melanoma tumour cells plays a key role in melanoma progression and 15 
is the mechanism by which melanoma cells regain OXPHOS capacity even in the presence of 16 
mitochondrial mutations. The studies outlined in this review indicate that targeting 17 
mitochondrial trafficking is a potential novel therapeutic approach for this highly refractory 18 
disease.  19 
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INTRODUCTION 24 
Melanoma is the most aggressive, deadly form of skin cancer (1) — despite accounting for 25 
only 5% of cases, it constitutes the main cause of deaths from skin cancer (2). It is also one of 26 
the fastest growing cancers worldwide (2), with the UK reporting 16,000 new cases every year 27 
(3). Along with the long-standing global trend of incidence rise (4), worldwide mortality rates 28 
are expected to increase from 61,850 in 2016 to 108,630 by 2040 (5).  29 
 30 
Melanoma is highly curable when limited to the primary site (6); metastatic melanoma, 31 
however, confers a poor prognosis of a median survival of six months (7). Current systemic 32 
therapies in patients with metastatic melanoma have a varied response rate, and tumour 33 
resistance develops rapidly in the majority of patients (6, 8-10). Further research is therefore 34 
required to understand the pathophysiology of this highly refractory disease, in the context 35 
of the role of metabolism (oxidative phosphorylation and/or glycolysis) in melanoma, and the 36 
interaction of melanoma with the tumour microenvironment (TME), which supports its 37 
survival and proliferation, and contributes to drug resistance.   38 
 39 
Primary cutaneous melanoma comprises a distinctly heterogeneous population of both 40 
cancerous and non-cancerous cells (11, 12), including fibroblasts, adipocytes and other niche 41 
cells such as mesenchymal stromal cells (MSCs), which make up the extracellular matrix, 42 
endothelial cells of the microvasculature, and immune cells (11-13). In addition to the cellular 43 
component of the tumour microenvironment (TME), the non-cellular component consists of 44 
several growth factors, chemokines and cytokines (14). Melanoma cells can manipulate the 45 
close association between themselves and the TME to facilitate tumour progression, invasion 46 
and metastasis (15, 16). Currently, immune cells in the TME have been the focus of much 47 
interest in an attempt to understand how an immunosuppressive microenvironment that 48 
allows for proliferation, growth and invasion of melanoma is created (10), while, by contrast, 49 
relative little research has been carried out on the role of MSCs in the TME in melanoma 50 
growth.  51 
 52 
In this review, we explore the symbiotic relationship between melanoma and MSCs and the 53 
ensuing metabolic advantage conferred on melanoma. We begin by describing the 54 
metabolism of melanoma and metabolic plasticity in melanoma cells before introducing 55 
metabolic symbiosis with MSCs and outlining potential mechanisms of transfer of 56 
mitochondrial DNA from MSCs to melanoma to facilitate oxidative phosphorylation.  57 
 58 
MSCs IN THE TME 59 
MSCs — spindle-shaped cells that are present in bone marrow, adipose, skin, umbilical cord, 60 
blood and various other tissues (17-20) — are highly proliferative and can differentiate into 61 
various cells such as osteoblasts, chondrocytes and adipocytes (17-19). These properties, in 62 
addition to their ability to home towards injured tissue, can be exploited by melanoma, which, 63 
like many other solid cancers, behaves like tissues that do not heal (21, 22): increasing 64 
evidence has shown that, like a chronic, non-healing wound, melanoma secretes 65 
chemoattractants (23), similar to those used in inflammatory signalling pathways (24), to 66 
attract and direct MSCs towards the tumour sites and form part of the TME to contribute 67 
towards tumour progression, invasion and metastasis (23, 25-28).  68 
 69 
 70 
  71 
MSCs and melanoma growth 72 
A positive effect for MSCs on tumour incidence was first demonstrated by co-injecting 73 
allogeneic mice with B16 melanoma cells and MSCs: not only was the incidence of tumour 74 
formation 100% when the melanoma cells and MSCs were injected together versus 0% in the 75 
control group (29, 30), but the onset of tumour formation was faster when soluble MSC-76 
derived factors were added (31). Kucerova et al. demonstrated this increased tumour 77 
incidence and growth using the human melanoma cell line A375 and human MSCs, as well as 78 
showing that this increase was dependent on the dose of MSCs (32). MSCs also abrogated 79 
tumour latency in vivo for low numbers of cells that would otherwise not normally produce 80 
tumours if injected alone (32). Furthermore, MSCs were shown to protect melanoma cells 81 
from sustaining cellular stress in response to systemic treatment, such as doxorubicin, and 82 
cytotoxicity by inhibiting apoptosis. Notably, the effect of MSCs on tumour initiation was 83 
reported in experiments using low volumes of A375 melanoma cells, mimicking minimal 84 
residual disease that is common following radiotherapy treatment. Together, these data 85 
demonstrate the pro-oncogenic role of MSCs on melanoma growth. 86 
 87 
Additional pro-oncogenic roles of MSCs  88 
MSCs also display various other pro-oncogenic behaviours, which are outlined here but not 89 
covered in detail as they are not the focus of this review. MSCs have been reported to increase 90 
the motility and invasiveness of melanoma by communicating with melanoma-derived 91 
exosomes, to manipulate melanoma cells towards a more metastatic phenotype via the 92 
process of epithelial–mesenchymal transition (EMT) (33) and by increasing the porosity of 93 
blood vessels, thereby facilitating tumour migration (33). Current reports have demonstrated 94 
the ability of MSCs to support neovascularisation in a mouse model of melanoma through the 95 
secretion of pro-angiogenic factors (27, 28, 34). Kucerova et al. demonstrated enhanced 96 
melanoma growth as a result of this proangiogenic cellular milieu created by the mutual 97 
crosstalk between melanoma and MSCs (32). In addition to the secretion of various factors, 98 
Vartanian et al. provided direct evidence that melanoma can educate MSCs to engage in 99 
vasculogenic mimicry, a process in which MSCs adopt certain endothelial-cell-like properties 100 
to directly contribute to the formation of the tumour vasculature (28). Several studies have 101 
also demonstrated the ability of MSCs to differentiate into carcinoma-associated fibroblasts 102 
(CAFs) (28, 34), a key cellular component of the growth-supporting TME, aiding the formation 103 
of the stem-cell niche and promoting stemness in the tumour (23, 35). Not only do these CAFs 104 
and MSCs promote tumour growth, but they have also been shown to have 105 
immunomodulatory functions — for example, reducing T-cell proliferation and the number 106 
of tumour-infiltrating T and B cells in vivo, and producing cytokines — thereby creating a 107 
highly effective immunosuppressive TME for melanoma proliferation (23, 36).  108 
 109 
MSC–melanoma symbiosis confers metabolic advantage 110 
The processes of MSC-mediated tissue repair, which involves activation, migration and 111 
homing to TME, and MSC differentiation and subsequent secretion of factors (by both 112 
melanoma cells and MSCs) produce a strong pro-oncogenic symbiotic relationship between 113 
MSCs and melanoma cells (21). This symbiotic relationship provides a metabolic advantage 114 
that is effective for melanoma proliferation and metastasis (37-39). Given the significance of 115 
metabolism in melanoma, supported by the growing evidence of its impact on the efficacy of 116 
current systemic therapies for this highly refractory disease (38), below we explore the 117 
symbiotic relationship between MSCs and melanoma, and how it might arise.  118 
  119 
METABOLISM OF MELANOMA 120 
Due to its significant influence on all aspects of tumorigenesis, metabolic reprogramming has 121 
been widely accepted as one of the hallmarks of cancer (40). Determining the biochemical 122 
pathway that melanoma cells use for energy production allows researchers to understand the 123 
influence of metabolism on the symbiotic relationship between melanoma and MSCs and its 124 
corresponding pro-oncogenic role (41). 125 
 126 
Glycolysis in melanoma 127 
In the 1920s, Warburg reported that, even in presence of oxygen, cancer cells take up glucose 128 
for glycolysis (42). This preferential method for energy production adopted by cancers was 129 
termed ‘aerobic glycolysis’ (also known as the Warburg effect) and was demonstrated to 130 
provide ATP necessary for survival and proliferation of the tumour (43).  131 
 132 
Melanoma has been demonstrated to be associated with a glycolytic phenotype (44, 45). 133 
Aerobic glycolysis in melanoma cells is driven by a multitude of factors, including activation 134 
of oncogenes, the presence of a hypoxic TME and an absence of tumour suppressors (46). 135 
Approximately 50–60% of melanomas contain a BRAF gene mutation (47), the most frequent 136 
of which (BRAFV600E, accounting for 90% of BRAF mutations (48) and rendering the gene 137 
product B-Raf constitutively active (49)) has been shown to be associated with higher glucose 138 
uptake and subsequent glycolysis (50). B-Raf activates the mitogen-activated protein kinase 139 
(MAPK) pathway, which promotes hypoxia-inducible factor 1α [HIF1α (master regulator of 140 
glycolysis)], resulting in an increase in glycolysis (50). Furthermore, B-Raf inhibits 141 
microphthalmia-associated transcription factor (MITF) and peroxisome proliferator-activated 142 
receptor-gamma coactivator 1α (PGC-1α), thereby inhibiting oxidative phosphorylation 143 
(OXPHOS) (43, 51, 52). OXPHOS is the main pathway for energy production in mitochondria 144 
via aerobic respiration. Providing direct evidence for this B-Raf mediated upregulation of 145 
aerobic glycolysis, Hall et al.(44) demonstrated a 14–16-fold higher extracellular acidification 146 
rate (ECAR, resulting from respiratory and glycolytic acidification) in melanoma cells 147 
compared to melanocytes. Furthermore, treatment with the glycolysis inhibitor 2-Deoxy-D-148 
glucose (2-DG) induced a significant drop in ATP production by melanoma cells, causing them 149 
instead to revert to OXPHOS for energy production. Analysis of the ECAR (a surrogate marker 150 
for glycolysis) and oxygen consumption rate (OCR; a surrogate marker for OXPHOS) in these 151 
cells uncovered a lower OCR/ECAR ratio, indicating the upregulation of glycolysis rather than 152 
low oxygen consumption or lower OXPHOS capacity. In fact, the absolute OCR values were 153 
higher in melanoma cell lines compared to melanocytes, with corresponding high OXPHOS 154 
enzyme activity.  Therefore, although glycolysis is upregulated in melanoma, OXPHOS also 155 
plays a role. 156 
 157 
Oxidative phosphorylation in melanoma 158 
Whether a specific metastatic lesion relies on either glycolysis or OXPHOS depends upon the 159 
heterogeneity of individual tumour types (53). Tumours behave individually, with each cancer 160 
demonstrating its own metabolic properties (46, 53). To add further complexity, even within 161 
an individual tumour, the constituent cells can be heterogeneous, displaying different energy 162 
metabolic phenotypes (46). For example, large B cell lymphomas can be split into a low 163 
OXPHOS subset and a high OXPHOS subset; the latter subset show an upregulation of 164 
mitochondrial electron transport chain components (54). Whilst many melanomas have an 165 
aerobic glycolytic phenotype, a subset has been shown to present with higher OXPHOS 166 
phenotype (38, 52). Fischer et al. have identified that 35–50% of BRAF-mutant and wild-type 167 
cell lines and patient samples can be categorised into this subset (38), indicating that a 168 
significant proportion of melanoma cells present with a higher OXPHOS phenotype. PGC-1α 169 
is a member of a family of transcriptional coactivators that play a central role in the regulation 170 
of cellular energy metabolism and mitochondrial biogenesis (55). Regulatory mechanisms to 171 
suppress OXPHOS mediated via the PGC-1α pathway fail to occur in high OXPHOS melanomas 172 
(38). Higher PGC-1α levels are correlated with poorer survival in melanoma patients (52). The 173 
PGC-1α-driven high OXPHOS subset demonstrated an improved tolerance to the damaging 174 
effects of reactive oxygen species (ROS), indicating their increased ability to survive under 175 
conditions of oxidative stress (52). In vivo experiments in mice demonstrated that PGC-1α 176 
knockdown resulted in reduced metastasis of melanoma (56), highlighting the pro-oncogenic 177 
role of OXPHOS in melanoma progression and metastasis.   178 
 179 
OXPHOS and glycolysis in melanoma 180 
Ho et al.(57) suggested that both OXPHOS and glycolysis play a significant role in the 181 
progression of melanoma and generation of ATP. They discovered two patient populations 182 
within their melanoma cohorts: one with high serum levels of lactate dehydrogenase (LDH) 183 
and one with normal serum LDH levels. The high serum LDH population had a corresponding 184 
high ECAR, suggesting that glycolysis was the predominant metabolic pathway. By contrast, 185 
in the normal serum LDH population, the tumours demonstrated elevation of several OXPHOS 186 
enzymes and higher OCR, indicating that OXPHOS was the predominant metabolic pathway. 187 
However, it is important to note that, although high serum LDH levels are associated with 188 
poor prognosis in metastatic melanoma patients (58), serum LDH levels might not necessarily 189 
always be a marker of tumour-associated increased cell turnover, as patients can have high 190 
LDH levels and perform poor clinically due to other factors such as tissue damage, severe 191 
infections and renal failure (59). The OCR rates were higher in both populations of melanoma 192 
patients, as well as in melanoma samples from patient tumour biopsy samples and cell lines 193 
in culture, compared to normal melanocytes. Thus, OXPHOS and glycolysis both play a 194 
significant role in melanoma metabolism (60, 61). 195 
 196 
METABOLIC PLASTICITY 197 
Although it is simpler to categorise melanoma into a glycolytic or OXPHOS phenotype, an 198 
increasing body of evidence suggests that the nature of metabolic phenotypes in melanoma 199 
is dynamic — this is termed ‘metabolic plasticity’ (38, 40). Jose et al.(40) demonstrated that 200 
the metabolic phenotype of melanoma is not fixed during tumorigenesis and, in fact, 201 
melanoma has a ‘hybrid’ glycolysis/OXPHOS metabolic phenotype, intuitively conferring 202 
selective advantages on tumour cells (45). Importantly, this hybrid phenotype provides 203 
tumour cells with the flexibility to use different energy sources to meet their bioenergetic 204 
needs in the different and changing TME (62). In a glucose-deprived environment, tumour 205 
cells are metabolically reprogrammed towards elevated levels of OXPHOS with decreased 206 
glycolysis, whereas in hypoxic conditions, the melanoma cells preferentially use glycolysis, 207 
uncoupling from the TCA cycle and attenuating mitochondrial respiration (45).  208 
 209 
Metabolic plasticity confers on melanoma cells not only the ability to adapt to harsh TME 210 
conditions but also a degree of chemoresistance, thereby providing a survival advantage in 211 
treatment-induced conditions (38). The use of targeted systemic therapy such as BRAF 212 
inhibitors (e.g. vemurafenib) to target BRAFV600E is associated with a switch from glycolysis 213 
to OXPHOS (63). Similarly, Haq et al. demonstrated that treatment with MAPK inhibitors 214 
resulted in increased PGC-1α-driven OXPHOS (51). Notably, an increase in PGC-1α-driven 215 
OXPHOS is observed in 30–50% of BRAF-mutant melanomas with de novo and acquired 216 
resistance to MAPK inhibitors (64)and, in these circumstances, PGC-1α knockdown resulted 217 
in reduced tumour growth (64). This metabolic switch from glycolysis to OXPHOS and the 218 
corresponding adaptive resistance was observed in patients treated with inhibitors of BRAF 219 
or MEK (MAPK and ERK kinase; an upstream activator of MAPK), alongside increased 220 
mitochondrial content, mitochondrial activity and mitochondrial oxidative capacity (37, 65-221 
68). These observations highlight the ability of melanoma to redirect the metabolic 222 
phenotypes to confer multiple pathways of chemoresistance. Collectively, it is clear that 223 
metabolic plasticity confers a significant survival advantage on cancer cells. 224 
 225 
METABOLIC SYMBIOSIS 226 
Within melanoma tumours, the extent of tissue perfusion and oxygenation depends on the 227 
location and physical distance of the tumour cells from the local vasculature (57). Accordingly, 228 
melanoma cells located in the poorly perfused centre of tumour masses are more likely to be 229 
predominantly dependent on glycolysis, whereas tumour cells closer to the vasculature at the 230 
periphery are more likely to be dependent on OXPHOS (57). It has, however, been proposed 231 
that these two spatially distinct cell populations might be linked, such that the end products 232 
from glycolysis (e.g. lactate) are utilised to feed into the TCA cycle for OXPHOS (57).  233 
 234 
Indeed, Ho et al. (57) reported that, although melanoma patients showed high levels of serum 235 
LDH, monocarboxylate transporters MCT4, (the principal transporter for lactate efflux (69) 236 
and a downstream effector of hypoxia-inducible factor (HIF)-1a (70)), indicating that the 237 
melanoma cells predominantly used glycolysis for energy production, the serum lactate levels 238 
remained constant. Although it is plausible that the lactate levels might not be affected by 239 
the tumour, the above data demonstrating upregulation of glycolysis make it more likely that 240 
the lactate levels remain unchanged due to other processes. Ho et al. suggested that 241 
increased levels of lactate resulting from glycolysis are taken up by the metabolically 242 
symbiotic melanoma cells that use OXPHOS as their primary mechanism of energy 243 
production. When enzymes associated with OXPHOS and glycolysis were both expressed at 244 
higher levels, it was evident that OXPHOS and glycolysis were both upregulated in melanoma, 245 
compared to normal tissues, demonstrating a further stage to metabolic plasticity (57). This 246 
co-operation of both OXPHOS and glycolysis occurring at the same time has been coined 247 
‘metabolic symbiosis’ (Figure 1A). Several papers (71) have reported this phenomenon and 248 
demonstrated its importance in melanoma initiation, growth and metastasis.  249 
 250 
THE REVERSE WARBURG EFFECT 251 
In vivo work carried out over the past decade has demonstrated that metabolic 252 
reprogramming involves not only cancer cells but also the MSCs and CAFs in the TME (62, 72). 253 
Whereas the Warburg effect refers to glycolysis being the preferential method of energy 254 
production in tumour cells, according to the ‘Reverse Warburg’ effect, tumour cells, by 255 
secreting ROS (by-product of OXPHOS melanoma cells), stimulate cells in the surrounding 256 
TME to undergo aerobic glycolysis, resulting in the secretion of metabolites, such as lactate, 257 
into the TME via MCT4 (73). These metabolic intermediates can be taken up by tumour cells, 258 
via MCT1, to feed into the TCA cycle for OXPHOS-mediated energy production (74), similar to 259 
the situation in metabolic symbiosis outlined above. Loss of Cav-1, a protein involved in 260 
endocytosis and vesicular transport, in TME cells results in a positive-feedback loop of 261 
oxidative stress in these cells, consequently increasing OXPHOS in tumour cells (62). This 262 
Reverse Warburg effect was initially reported in a variety of cancers (38) but is as yet to be 263 
fully elucidated in melanoma. However, taking together the use of OXPHOS in the periphery 264 
of melanomas, the metabolic symbiosis reported earlier, and Ho et al.’s findings of increased 265 
expression of MTC1 and MTC4 in melanoma (57), it is likely that the Reverse Warburg effect 266 
occurs in the TME of melanoma (Figure 1B). 267 
 268 
The above research has demonstrated that the oncological hallmark of altered metabolism is 269 
not only due to the regulation for growth, but can be primary cause for tumour initiation, 270 
progression, metastasis and chemoresistance. Due to the heterogeneic dynamism (metabolic 271 
plasticity) between glycolysis and OXPHOS of melanoma, the effective blockade of OXPHOS 272 
(e.g. using inhibitors of mTORC1) as well as glycolysis (e.g. MAPK pathway inhibitors) has been 273 
shown to resensitise melanomas that are resistant to inhibitors of BRAF and other MAPK 274 
pathway components [AU: OK?], and thus to be a promising form of treatment (64, 75). 275 
Previous work has shown that upregulation of aerobic glycolysis in tumour cells is due to the 276 
presence of mitochondrial DNA (mtDNA) mutations, which were assumed to impair OXPHOS 277 
capacity. However, several papers have demonstrated that these mtDNA mutations do not 278 
necessarily equate to a compromise in OXPHOS capacity. Conversely, although cancer cells 279 
retain OXPHOS capacity, they can also possess mtDNA mutations due to damaging effects of 280 
higher ROS secretion in mitochondria from inefficient repair mechanisms, close proximity and 281 
vulnerability of mtDNA (43, 46, 50, 76). Consequently, further research was carried out to 282 
discover why melanoma cells with mtDNA mutations still possessed the capacity to use 283 
OXPHOS for energy production, as well as to develop more effective OXPHOS therapies 284 
against melanoma.  285 
 286 
  287 
MITOCHONDRIAL TRANSFER 288 
In 2010, Berridge and Tan (77) designed a model of B16 melanoma cell lines with severe 289 
mtDNA damage caused by the mitochondrial gene deletion ρ0 to investigate mitochondrial 290 
OXPHOS. The authors observed that not only did the ρ0 cells grow at half the rate of their 291 
parental cells in vitro, but they also underwent delayed primary subcutaneous melanoma 292 
growth and reduced lung metastasis formation in mouse models in vivo, compared to B16 293 
parental cells (77). At the time these studies were carried out, this delay was suggested to be 294 
due to the time taken to adapt to auxotrophic requirements and local microenvironmental 295 
conditions. However, a series of in vitro experiments demonstrating mitochondrial trafficking 296 
in other cancers (Table 1) as a prerequisite for aerobic respiration, tumour growth, metastasis 297 
and chemoresistance (78-88) implied that the delay might be the result of mitochondrial 298 
trafficking from MSCs in the TME to tumours. Additional investigations in other cancers into 299 
the mechanisms and stimuli behind mitochondrial trafficking, such as NAPDH-oxidase-2-300 
driven and CD38-driven in acute myeloid leukaemia and multiple myeloma, respectively, have 301 
led to the development of effective therapeutic agents targeting mitochondrial trafficking, 302 
with demonstrated effective tumour regression (83, 84, 89). 303 
 304 
Mitochondrial transfer in melanoma 305 
Consistent with the results obtained in other tumours, Tan et al. (88) subsequently 306 
demonstrated, in 2015, that the delay in melanoma tumour growth when B16ρ0 cells were 307 
injected in NOD/SCID mice was due to the time taken for these cells to acquire mtDNA from 308 
the TME in vivo. In 2017, Dong et al. (90) demonstrated that the tumours that grew from 309 
injected B16ρ0 cells in vivo, after a delay, contained host TME mtDNA (confirmed via single-310 
cell droplet PCR methods), and that the B16ρ0 cells had acquired mitochondria from host 311 
MSCs by the presence of double-positive cells when B16ρ0 cells with nuclear-targeted blue 312 
fluorescent protein were injected into C57BL/GN mice with red fluorescent mitochondria in 313 
mouse MSCs.  314 
 315 
The primary role of mitochondria is to produce energy via OXPHOS (91), and mtDNA encodes 316 
peptides that are essential for this task  (92). Accordingly, Dong et al. demonstrated that the 317 
injected B16ρ0 cells that gained mtDNA subsequently contained mtDNA-encoded proteins 318 
and fully assembled respirasomes, with a higher OCR and increased ATP production than 319 
injected B16ρ0 cells that failed to gain mtDNA. These results demonstrated that the mtDNA 320 
transferred to the B16ρ0 cells was functional and conferred similar OXPHOS respiration rates 321 
and respiration recovery to those of their parental B16 cells. 322 
 323 
Finally, Dong et al. (90) provided direct evidence for the requirement of OXPHOS respiration 324 
mediated by mtDNA transfer from MSCs to melanoma cells in tumour formation. B16ρ0 cells 325 
with OXPHOS respiration suppressed (via inhibition of the catalytic subunits of CI and CII) 326 
formed tumours with an even longer lag period of 15–40 days compared with B16ρ0 cells 327 
without OXPHOS suppressed, in vivo. A similar pattern was observed for parental B16 cells 328 
with OXPHOS knocked down (90). This indicates a shift in viewpoint regarding cancer 329 
metabolism, with mitochondrial DNA mutations not compromising OXPHOS capacity. These 330 
results collectively demonstrate that melanoma cells gain mtDNA from the MSCs and their 331 
subsequent rapid OXPHOS recovery is a prerequisite for driving efficient tumour formation. 332 
Although mitochondrial trafficking in melanoma has only been shown in the murine B16 cell 333 
line, the extensive experiments mentioned above, coupled with the importance of 334 
mitochondrial trafficking demonstrated in several other human cancers, make it very 335 
plausible that mitochondrial trafficking plays a vital role in human melanoma progression. A 336 
major gap in the literature therefore exists, and further experiments are required to 337 
demonstrate role of mitochondrial trafficking in other cell lines and human melanoma. 338 
 339 
Despite intracellular transfer of mtDNA being the most likely transfer mechanism, other 340 
possible explanations for mtDNA acquisition and respiration recovery have been suggested. 341 
First, it is plausible that a few tumour cells with mitochondria and mtDNA replicate their 342 
mtDNA and proliferate at much faster rate than tumour cells without mtDNA, and that the 343 
tumour cells without mtDNA might then be progressively removed by autophagy. However, 344 
markers for autophagy, such asLC3A11 protein, were lower in B16ρ0 cells compared with B16 345 
cell lines, suggesting that this is not the case (90). Another possible explanation is the 346 
presence of B16ρ0 cells that contained residual undetectable mtDNA. However, this theory 347 
was rejected by Dong et al., who used assays that were able to detect heteroplasmy down to 348 
0.5%. The absence of mtDNA in ρ0 cells was further reinforced by confocal microscopy 349 
analysis, and the absence of any latent respirasomes/supercomplexes prior to mtDNA 350 
acquisition was shown via native blue gel electrophoresis. Thus, the only plausible mechanism 351 
of mtDNA acquisition in tumour cells is thought to be transfer from host TME.  352 
 353 
  354 
MECHANISM OF MTDNA TRANSFER 355 
Studies carried out over the past 15 years have demonstrated that mitochondria can cross 356 
cell boundaries and be transferred horizontally between cells (93). The main mechanisms of 357 
mtDNA transfer from MSCs to tumour cells are tunnelling nanotubules (TNTs), microvesicles 358 
and gap junctions, although other plausible mechanisms exist that require further research, 359 
such as cell fusion and direct mtDNA secretion into extracellular media (93-95) (Figure 2).  360 
 361 
Tunnelling nanotubules  362 
Tunnelling nanotubes (TNTs) are filopodial extensions (bundles of rod-like shaped parallel 363 
actin filaments) of cell cytoplasm that connect two cells via open-ended channels (96, 97) 364 
(Figure 2A). TNTs have been shown to facilitate the transfer of biomaterial such as cellular 365 
organelles, cytoplasmic molecules and membrane molecules between cells (97). Koyangi et 366 
al. were the first to document (in 2005) whole mitochondrial transfer through TNTs from 367 
cardiomyocytes to endothelial progenitor cells (98); mitochondrial transfer into melanoma 368 
via TNTs was not demonstrated until 2017 (90). 369 
 370 
Extracellular vesicles (EVs) 371 
mtDNA can also be horizontally transferred through the movement of mitochondrial-derived 372 
products or intact mitochondria in EVs — exosomes or microvesicles, respectively (93) (Figure 373 
2B). Exosomes are small (30-100nM in diameter) membrane-encompassed vesicles formed in 374 
the endosomal pathway (94, 99, 100). During the endosomal pathway, segments of 375 
endosomal membrane bud inside the endosome as a collection of intraluminal vesicles (ILVs) 376 
to form multivesicular bodies (MVBs) (94). These MVBs move to the cell's surface plasma 377 
membrane release ILVs (exosomes) externally into the extracellular media (94, 101). In 378 
contrast, microvesicles, largest EVs (50-1000nM in diameter) (99), are formed directly from 379 
external budding and fission of the plasma membrane of the cell into the extracellular media 380 
(94, 102, 103). Guescini et al. demonstrated the potential of exosomes as vectors for 381 
mitochondrial transfer in glioblastoma and astrocyte cells, which routinely secrete EVs into 382 
the intercellular space (104). Isolation of these purified EVs demonstrated the presence of 383 
mtDNA and absence of nuclear DNA. Furthermore, high mtDNA levels and mitochondrial 384 
proteins were shown to be present in exosomes released into the intercellular media by 385 
skeletal muscle cells (105). Although these papers implied that EVs could function as mtDNA 386 
carriers [AU: OK?], Islam et al. (106) were the first to demonstrate mitochondrial transfer 387 
from MSCs to lung alveolar epithelial cells via EVs in vivo. Furthermore, Sinclair et al. (95) 388 
demonstrated that mitochondrial trafficking was reduced by 34.7% after inhibition of 389 
endocytosis of EVs into lung epithelial cells. These results provide in vivo evidence for the 390 
transfer of mitochondria from MSCs to tumour cells via EVs, although transfer from MSCs to 391 
melanoma by this means has not yet been reported. 392 
 393 
Gap junctions 394 
Gap junctions are intercellular channels composed of two connexons, joined together in the 395 
intercellular space, that directly connect the cytoplasm of two different cells (107) (Figure 2C). 396 
Whereas TNTs facilitate long-distance communication, gap junctions promote close cell-to-397 
cell communication (107). Islam et al. (106) demonstrated gap-junction-mediated 398 
mitochondrial transfer from MSCs and a subsequent increase in ATP production for tissue 399 
repair in alveolar epithelial cells in an in vivo mouse model of acute lung injury. These results 400 
were reproducible in other models comprising MSCs with haematopoietic stem cells (108) or 401 
epithelial cells (95), with a increase in mtDNA transfer and mitochondrial content in recipient 402 
cells. Most current literature agrees that gap junctions are one of the main mechanisms for 403 
mitochondrial transfer from MSCs to the target cell (93), although this method of 404 
mitochondrial transfer has so far not been demonstrated in melanoma.  405 
 406 
Alternative mechanisms 407 
In the three main transfer mechanisms outlined above, mitochondrial transfer is quick and 408 
unidirectional. However, Sinclair et al. (95) demonstrated that, although inhibition of all these 409 
mechanisms reduced mitochondrial transfer, it did not completely prevent it, indicating the 410 
possibility that additional mechanisms exist.  411 
 412 
Cell fusion, whereby the plasma membranes of two cells fuse and merge together whilst 413 
retaining their nuclei (94), is a contentious form of intercellular communication (Figure 2D). 414 
Evidence for mitochondrial transfer via cell fusion remains scarce, as it is difficult to ascertain 415 
whether the host cell remains as a host cell after fusion (93). Wada et al. modelled cell fusion 416 
in vitro by developing microfluidic devices that fused paired single cells together through a 417 
microslit to form a cytoplasmic connection (109). They demonstrated that this cell fusion 418 
system enabled whole mitochondria to be transferred from parental osteosarcoma cells to 419 
ρ0 osteosarcoma cells and that, after transfer, the fused cells would spontaneously 420 
disconnect and recover in normal culture. Further data are required to substantiate cell fusion 421 
as a method of transfer from MSCs to cancer. 422 
 423 
Although Guescini et al. demonstrated the transfer of mtDNA via EVs, they also showed that 424 
a significant proportion of mtDNA was free in the intercellular media (104). Other studies 425 
have identified the release of endogenous mtDNA, as ‘damage’-associated molecular 426 
patterns (DAMPs), into the intercellular media in response to injury and inflammation (110). 427 
As carcinogenesis mimics a chronic inflammatory state (111), it is likely that tumours secrete 428 
mtDNA into the media, identifying mtDNA secretion into the media as another potential 429 
method of mitochondrial transfer (Figure 2E).  430 
 431 
CONCLUSIONS AND DISCUSSION  432 
In melanomas, the TME is known to be important for conferring treatment resistance to the 433 
tumour cells. The bulk of the TME is formed by MSCs and the cells they give rise to. In contrast 434 
with melanoma cells, MSCs have stable genomes, and so offer themselves as a better 435 
potential for therapeutic targeting. OXPHOS plays a significant role in metabolic plasticity, 436 
metabolic symbiosis and the homeostasis of the high OXPHOS subset in melanoma, allowing 437 
the development of treatment resistance. MSCs ensure that melanoma cells can retain an 438 
independent OXPHOS capacity via mitochondrial trafficking to melanoma cells. Mitochondrial 439 
trafficking has been shown to be a prerequisite for continued aerobic respiration, subsequent 440 
tumour growth, metastasis and the development of chemoresistance and, consequently, 441 
inhibition of this process has been integrated into the treatment pathway for other cancers 442 
(112, 113).  443 
  444 
In this review, we have highlighted mitochondrial trafficking as a potential target to combat 445 
the prevalent resistance to current therapies in melanoma. We also outline the need for 446 
further research into the different potential mechanisms of mitochondrial trafficking. As 447 
mentioned above, only TNT-mediated transfer has definitively been demonstrated as a 448 
means for mitochondrial transfer to melanomas; the fact that EVs and gap junctions are 449 
commonly employed for mtDNA transfer by most cancers highlights the need for further 450 
research to elucidate if these important mechanisms occur in melanoma as well, to facilitate 451 
the development of targeted therapeutics against this highly refractory disease.  452 
 453 
  454 
ADDITIONAL INFORMATION 
Acknowledgements: Not Applicable 
Contributorship Statement: 
My co-author and I participated in the research of this paper and assisted in all of the following 
parts: 
1. Guarantor of integrity of the entire study: Prakrit Kumar, Marc Moncrieff, Kristian Bowles 
and Stuart Rushworth  
2. Study concepts and design: Prakrit Kumar, Stuart Rushworth, Marc Moncrieff  
3. Literature research: Prakrit Kumar, Stuart Rushworth  
4. Figure preparation: Prakrit Kumar, Jamie Moore, Stuart Rushworth  
5. Manuscript preparation: Prakrit Kumar, Jamie Moore, Marc Moncrieff, Kristian Bowles and 
Stuart Rushworth  
6. Manuscript critical revision and supervision: Prakrit Kumar, Jamie Moore, Marc Moncrieff, 
Kristian Bowles and Stuart Rushworth  
Ethics Approval: Not Applicable 
Consent for Publication: Not Applicable 
Data availability: Not Applicable 
Conflict of Interest: No potential conflict of interest relevant to this article was reported. All author 
information provided in the conflict of interest forms is current. 
Funding:  No external funding was used in the execution of this study  
REFERENCES 455 
1. Laikova KV, Oberemok VV, Krasnodubets AM, Gal'chinsky NV, Useinov RZ, Novikov IA, 456 
et al. Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and 457 
Antisense Oligonucleotides as Anticancer Drugs. Molecules. 2019;24(8). 458 
2. Liu Y, Sheikh MS. Melanoma: Molecular Pathogenesis and Therapeutic Management. 459 
Mol Cell Pharmacol. 2014;6(3):228. 460 
3. UK CR. Melanoma skin cancer statistics. 2019. 461 
4. Hartman RI, Lin JY. Cutaneous Melanoma-A Review in Detection, Staging, and 462 
Management. Hematol Oncol Clin North Am. 2019;33(1):25-38. 463 
5. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. 464 
Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 465 
250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and 466 
territories. Lancet. 2018;392(10159):2052-90. 467 
6. Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. 468 
Cancer Biol Ther. 2019;20(11):1366-79. 469 
7. Crosby T, Fish R, Coles B, Mason M. WITHDRAWN: Systemic treatments for metastatic 470 
cutaneous melanoma. Cochrane Database Syst Rev. 2018;2:CD001215. 471 
8. Polkowska M, Ekk-Cierniakowski P, Czepielewska E, Kozlowska-Wojciechowska M. 472 
Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patients-real-473 
world data. Eur J Clin Pharmacol. 2019;75(3):329-34. 474 
9. Spagnolo F, Ghiorzo P, Orgiano L, Pastorino L, Picasso V, Tornari E, et al. BRAF-mutant 475 
melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco 476 
Targets Ther. 2015;8:157-68. 477 
10. Wang P, Zhang X, Sun N, Zhao Z, He J. Comprehensive Analysis of the Tumor 478 
Microenvironment in Cutaneous Melanoma associated with Immune Infiltration. J Cancer. 479 
2020;11(13):3858-70. 480 
11. Cacho-Diaz B, Garcia-Botello DR, Wegman-Ostrosky T, Reyes-Soto G, Ortiz-Sanchez E, 481 
Herrera-Montalvo LA. Tumor microenvironment differences between primary tumor and 482 
brain metastases. J Transl Med. 2020;18(1):1. 483 
12. Pieniazek M, Matkowski R, Donizy P. Macrophages in skin melanoma-the key element 484 
in melanomagenesis. Oncol Lett. 2018;15(4):5399-404. 485 
13. Brandner JM, Haass NK. Melanoma's connections to the tumour microenvironment. 486 
Pathology. 2013;45(5):443-52. 487 
14. Chitty JL, Filipe EC, Lucas MC, Herrmann D, Cox TR, Timpson P. Recent advances in 488 
understanding the complexities of metastasis. F1000Res. 2018;7. 489 
15. Falletta P, Sanchez-Del-Campo L, Chauhan J, Effern M, Kenyon A, Kershaw CJ, et al. 490 
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and 491 
therapeutic resistance in melanoma. Genes Dev. 2017;31(1):18-33. 492 
16. Kim IS, Heilmann S, Kansler ER, Zhang Y, Zimmer M, Ratnakumar K, et al. 493 
Microenvironment-derived factors driving metastatic plasticity in melanoma. Nat Commun. 494 
2017;8:14343. 495 
17. Augello A, De Bari C. The regulation of differentiation in mesenchymal stem cells. Hum 496 
Gene Ther. 2010;21(10):1226-38. 497 
18. Keating A. Mesenchymal stromal cells. Curr Opin Hematol. 2006;13(6):419-25. 498 
19. Vater C, Kasten P, Stiehler M. Culture media for the differentiation of mesenchymal 499 
stromal cells. Acta Biomater. 2011;7(2):463-77. 500 
20. Lindner U, Kramer J, Rohwedel J, Schlenke P. Mesenchymal Stem or Stromal Cells: 501 
Toward a Better Understanding of Their Biology? Transfus Med Hemother. 2010;37(2):75-83. 502 
21. Nwabo Kamdje AH, Kamga PT, Simo RT, Vecchio L, Seke Etet PF, Muller JM, et al. 503 
Mesenchymal stromal cells' role in tumor microenvironment: involvement of signaling 504 
pathways. Cancer Biol Med. 2017;14(2):129-41. 505 
22. Wang H, Cao F, De A, Cao Y, Contag C, Gambhir SS, et al. Trafficking mesenchymal 506 
stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. 507 
Stem Cells. 2009;27(7):1548-58. 508 
23. Mirzaei H, Sahebkar A, Avan A, Jaafari MR, Salehi R, Salehi H, et al. Application of 509 
Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of 510 
Targeted Agents. Curr Med Chem. 2016;23(5):455-63. 511 
24. Chulpanova DS, Kitaeva KV, Tazetdinova LG, James V, Rizvanov AA, Solovyeva VV. 512 
Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor 513 
Treatment. Front Pharmacol. 2018;9:259. 514 
25. Reagan MR, Kaplan DL. Concise review: Mesenchymal stem cell tumor-homing: 515 
detection methods in disease model systems. Stem Cells. 2011;29(6):920-7. 516 
26. Ridge SM, Sullivan FJ, Glynn SA. Mesenchymal stem cells: key players in cancer 517 
progression. Mol Cancer. 2017;16(1):31. 518 
27. Suzuki K, Sun R, Origuchi M, Kanehira M, Takahata T, Itoh J, et al. Mesenchymal 519 
stromal cells promote tumor growth through the enhancement of neovascularization. Mol 520 
Med. 2011;17(7-8):579-87. 521 
28. Vartanian A, Karshieva S, Dombrovsky V, Belyavsky A. Melanoma educates 522 
mesenchymal stromal cells towards vasculogenic mimicry. Oncol Lett. 2016;11(6):4264-8. 523 
29. Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, Noel D. Earlier onset of 524 
syngeneic tumors in the presence of mesenchymal stem cells. Transplantation. 525 
2006;82(8):1060-6. 526 
30. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. Immunosuppressive 527 
effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 528 
2003;102(10):3837-44. 529 
31. Han Z, Tian Z, Lv G, Zhang L, Jiang G, Sun K, et al. Immunosuppressive effect of bone 530 
marrow-derived mesenchymal stem cells in inflammatory microenvironment favours the 531 
growth of B16 melanoma cells. J Cell Mol Med. 2011;15(11):2343-52. 532 
32. Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C. Tumor cell behaviour 533 
modulation by mesenchymal stromal cells. Mol Cancer. 2010;9:129. 534 
33. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. 535 
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic 536 
phenotype through MET. Nat Med. 2012;18(6):883-91. 537 
34. Kucerova L, Zmajkovic J, Toro L, Skolekova S, Demkova L, Matuskova M. Tumor-driven 538 
Molecular Changes in Human Mesenchymal Stromal Cells. Cancer Microenviron. 2015;8(1):1-539 
14. 540 
35. Kucerova L, Skolekova S, Demkova L, Bohovic R, Matuskova M. Long-term efficiency 541 
of mesenchymal stromal cell-mediated CD-MSC/5FC therapy in human melanoma xenograft 542 
model. Gene Ther. 2014;21(10):874-87. 543 
36. Ling W, Zhang J, Yuan Z, Ren G, Zhang L, Chen X, et al. Mesenchymal stem cells use 544 
IDO to regulate immunity in tumor microenvironment. Cancer Res. 2014;74(5):1576-87. 545 
37. Avagliano A, Fiume G, Pelagalli A, Sanita G, Ruocco MR, Montagnani S, et al. Metabolic 546 
Plasticity of Melanoma Cells and Their Crosstalk With Tumor Microenvironment. Front Oncol. 547 
2020;10:722. 548 
38. Fischer GM, Vashisht Gopal YN, McQuade JL, Peng W, DeBerardinis RJ, Davies MA. 549 
Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor 550 
microenvironment, and therapeutic implications. Pigment Cell Melanoma Res. 2018;31(1):11-551 
30. 552 
39. Lyssiotis CA, Kimmelman AC. Metabolic Interactions in the Tumor Microenvironment. 553 
Trends Cell Biol. 2017;27(11):863-75. 554 
40. Jose C, Bellance N, Rossignol R. Choosing between glycolysis and oxidative 555 
phosphorylation: a tumor's dilemma? Biochim Biophys Acta. 2011;1807(6):552-61. 556 
41. Bellance N, Benard G, Furt F, Begueret H, Smolkova K, Passerieux E, et al. Bioenergetics 557 
of lung tumors: alteration of mitochondrial biogenesis and respiratory capacity. Int J Biochem 558 
Cell Biol. 2009;41(12):2566-77. 559 
42. Warburg O, Wind F, Negelein E. The Metabolism of Tumors in the Body. J Gen Physiol. 560 
1927;8(6):519-30. 561 
43. Abildgaard C, Guldberg P. Molecular drivers of cellular metabolic reprogramming in 562 
melanoma. Trends Mol Med. 2015;21(3):164-71. 563 
44. Hall A, Meyle KD, Lange MK, Klima M, Sanderhoff M, Dahl C, et al. Dysfunctional 564 
oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by 565 
the (V600E)BRAF oncogene. Oncotarget. 2013;4(4):584-99. 566 
45. Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, et al. 567 
Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J 568 
Biol Chem. 2011;286(49):42626-34. 569 
46. Zheng J. Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation 570 
(Review). Oncol Lett. 2012;4(6):1151-7. 571 
47. Kim A, Cohen MS. The discovery of vemurafenib for the treatment of BRAF-mutated 572 
metastatic melanoma. Expert Opin Drug Discov. 2016;11(9):907-16. 573 
48. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF 574 
gene in human cancer. Nature. 2002;417(6892):949-54. 575 
49. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, et al. The role of 576 
BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85. 577 
50. Hosseini M, Kasraian Z, Rezvani HR. Energy metabolism in skin cancers: A therapeutic 578 
perspective. Biochim Biophys Acta Bioenerg. 2017;1858(8):712-22. 579 
51. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic 580 
BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell. 2013;23(3):302-581 
15. 582 
52. Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K, et al. PGC1alpha expression 583 
defines a subset of human melanoma tumors with increased mitochondrial capacity and 584 
resistance to oxidative stress. Cancer Cell. 2013;23(3):287-301. 585 
53. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim 586 
Biophys Acta. 2010;1805(1):105-17. 587 
54. Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, et al. Metabolic 588 
signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. 589 
Cancer Cell. 2012;22(4):547-60. 590 
55. Bost F, Kaminski L. The metabolic modulator PGC-1alpha in cancer. Am J Cancer Res. 591 
2019;9(2):198-211. 592 
56. LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, et al. 593 
PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells 594 
to promote metastasis. Nat Cell Biol. 2014;16(10):992-1003, 1-15. 595 
57. Ho J, de Moura MB, Lin Y, Vincent G, Thorne S, Duncan LM, et al. Importance of 596 
glycolysis and oxidative phosphorylation in advanced melanoma. Mol Cancer. 2012;11:76. 597 
58. Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, et al. Prognostic role 598 
of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 599 
studies. Acta Oncol. 2015;54(7):961-70. 600 
59. Farhana A, Lappin SL. Biochemistry, Lactate Dehydrogenase (LDH).  StatPearls. 601 
Treasure Island (FL)2020. 602 
60. Barbi de Moura M, Vincent G, Fayewicz SL, Bateman NW, Hood BL, Sun M, et al. 603 
Mitochondrial respiration--an important therapeutic target in melanoma. PLoS One. 604 
2012;7(8):e40690. 605 
61. Xu K, Mao X, Mehta M, Cui J, Zhang C, Xu Y. A comparative study of gene-expression 606 
data of basal cell carcinoma and melanoma reveals new insights about the two cancers. PLoS 607 
One. 2012;7(1):e30750. 608 
62. Jia D, Park JH, Jung KH, Levine H, Kaipparettu BA. Elucidating the Metabolic Plasticity 609 
of Cancer: Mitochondrial Reprogramming and Hybrid Metabolic States. Cells. 2018;7(3). 610 
63. Trotta AP, Gelles JD, Serasinghe MN, Loi P, Arbiser JL, Chipuk JE. Disruption of 611 
mitochondrial electron transport chain function potentiates the pro-apoptotic effects of 612 
MAPK inhibition. J Biol Chem. 2017;292(28):11727-39. 613 
64. Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, et al. Inhibition of 614 
mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1alpha and 615 
oxidative phosphorylation in melanoma. Cancer Res. 2014;74(23):7037-47. 616 
65. Figarola JL, Singhal J, Singhal S, Kusari J, Riggs A. Bioenergetic modulation with the 617 
mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of 618 
treatment-naive and vemurafenib-resistant melanomas. Oncotarget. 2018;9(97):36945-65. 619 
66. Ruocco MR, Avagliano A, Granato G, Vigliar E, Masone S, Montagnani S, et al. 620 
Metabolic flexibility in melanoma: A potential therapeutic target. Semin Cancer Biol. 621 
2019;59:187-207. 622 
67. Corazao-Rozas P, Guerreschi P, Andre F, Gabert PE, Lancel S, Dekiouk S, et al. 623 
Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon 624 
exposure to MAPK inhibitors. Oncotarget. 2016;7(26):39473-85. 625 
68. Audrito V, Manago A, Gaudino F, Deaglio S. Targeting metabolic reprogramming in 626 
metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT). 627 
Semin Cell Dev Biol. 2020;98:192-201. 628 
69. Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S. The low-affinity monocarboxylate 629 
transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J. 630 
2000;350 Pt 1:219-27. 631 
70. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, 632 
but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol 633 
Chem. 2006;281(14):9030-7. 634 
71. Ma L, Zong X. Metabolic Symbiosis in Chemoresistance: Refocusing the Role of Aerobic 635 
Glycolysis. Front Oncol. 2020;10:5. 636 
72. Porporato PE, Filigheddu N, Pedro JMB, Kroemer G, Galluzzi L. Mitochondrial 637 
metabolism and cancer. Cell Res. 2018;28(3):265-80. 638 
73. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, et al. 639 
Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor 640 
stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease, 641 
and "Neuron-Glia Metabolic Coupling". Aging (Albany NY). 2010;2(4):185-99. 642 
74. Gonzalez CD, Alvarez S, Ropolo A, Rosenzvit C, Bagnes MF, Vaccaro MI. Autophagy, 643 
Warburg, and Warburg reverse effects in human cancer. Biomed Res Int. 2014;2014:926729. 644 
75. Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative Phosphorylation 645 
as an Emerging Target in Cancer Therapy. Clin Cancer Res. 2018;24(11):2482-90. 646 
76. Krishnan KJ, Reeve AK, Samuels DC, Chinnery PF, Blackwood JK, Taylor RW, et al. What 647 
causes mitochondrial DNA deletions in human cells? Nat Genet. 2008;40(3):275-9. 648 
77. Berridge MV, Tan AS. Effects of mitochondrial gene deletion on tumorigenicity of 649 
metastatic melanoma: reassessing the Warburg effect. Rejuvenation Res. 2010;13(2-3):139-650 
41. 651 
78. Ahmad T, Mukherjee S, Pattnaik B, Kumar M, Singh S, Kumar M, et al. Miro1 regulates 652 
intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy. 653 
EMBO J. 2014;33(9):994-1010. 654 
79. Burt R, Dey A, Aref S, Aguiar M, Akarca A, Bailey K, et al. Activated stromal cells transfer 655 
mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress. Blood. 656 
2019;134(17):1415-29. 657 
80. Caicedo A, Fritz V, Brondello JM, Ayala M, Dennemont I, Abdellaoui N, et al. 658 
MitoCeption as a new tool to assess the effects of mesenchymal stem/stromal cell 659 
mitochondria on cancer cell metabolism and function. Sci Rep. 2015;5:9073. 660 
81. Cho YM, Kim JH, Kim M, Park SJ, Koh SH, Ahn HS, et al. Mesenchymal stem cells 661 
transfer mitochondria to the cells with virtually no mitochondrial function but not with 662 
pathogenic mtDNA mutations. PLoS One. 2012;7(3):e32778. 663 
82. Lin HY, Liou CW, Chen SD, Hsu TY, Chuang JH, Wang PW, et al. Mitochondrial transfer 664 
from Wharton's jelly-derived mesenchymal stem cells to mitochondria-defective cells 665 
recaptures impaired mitochondrial function. Mitochondrion. 2015;22:31-44. 666 
83. Marlein CR, Piddock RE, Mistry JJ, Zaitseva L, Hellmich C, Horton RH, et al. CD38-Driven 667 
Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma. Cancer Res. 668 
2019;79(9):2285-97. 669 
84. Marlein CR, Zaitseva L, Piddock RE, Robinson SD, Edwards DR, Shafat MS, et al. NADPH 670 
oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells 671 
to leukemic blasts. Blood. 2017;130(14):1649-60. 672 
85. Moschoi R, Imbert V, Nebout M, Chiche J, Mary D, Prebet T, et al. Protective 673 
mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during 674 
chemotherapy. Blood. 2016;128(2):253-64. 675 
86. Pasquier J, Guerrouahen BS, Al Thawadi H, Ghiabi P, Maleki M, Abu-Kaoud N, et al. 676 
Preferential transfer of mitochondria from endothelial to cancer cells through tunneling 677 
nanotubes modulates chemoresistance. J Transl Med. 2013;11:94. 678 
87. Spees JL, Olson SD, Whitney MJ, Prockop DJ. Mitochondrial transfer between cells can 679 
rescue aerobic respiration. Proc Natl Acad Sci U S A. 2006;103(5):1283-8. 680 
88. Tan AS, Baty JW, Dong LF, Bezawork-Geleta A, Endaya B, Goodwin J, et al. 681 
Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of 682 
cancer cells without mitochondrial DNA. Cell Metab. 2015;21(1):81-94. 683 
89. Mistry JJ, Moore JA, Kumar P, Marlein CR, Hellmich C, Pillinger G, et al. Daratumumab 684 
inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from 685 
mesenchymal stromal cells. Haematologica. 2020. 686 
90. Dong LF, Kovarova J, Bajzikova M, Bezawork-Geleta A, Svec D, Endaya B, et al. 687 
Horizontal transfer of whole mitochondria restores tumorigenic potential in mitochondrial 688 
DNA-deficient cancer cells. Elife. 2017;6. 689 
91. Friedman JR, Nunnari J. Mitochondrial form and function. Nature. 690 
2014;505(7483):335-43. 691 
92. Desler C, Marcker ML, Singh KK, Rasmussen LJ. The importance of mitochondrial DNA 692 
in aging and cancer. J Aging Res. 2011;2011:407536. 693 
93. Torralba D, Baixauli F, Sanchez-Madrid F. Mitochondria Know No Boundaries: 694 
Mechanisms and Functions of Intercellular Mitochondrial Transfer. Front Cell Dev Biol. 695 
2016;4:107. 696 
94. Murray LMA, Krasnodembskaya AD. Concise Review: Intercellular Communication Via 697 
Organelle Transfer in the Biology and Therapeutic Applications of Stem Cells. Stem Cells. 698 
2019;37(1):14-25. 699 
95. Sinclair KA, Yerkovich ST, Hopkins PM, Chambers DC. Characterization of intercellular 700 
communication and mitochondrial donation by mesenchymal stromal cells derived from the 701 
human lung. Stem Cell Res Ther. 2016;7(1):91. 702 
96. Bukoreshtliev NV, Wang X, Hodneland E, Gurke S, Barroso JF, Gerdes HH. Selective 703 
block of tunneling nanotube (TNT) formation inhibits intercellular organelle transfer between 704 
PC12 cells. FEBS Lett. 2009;583(9):1481-8. 705 
97. Rustom A, Saffrich R, Markovic I, Walther P, Gerdes HH. Nanotubular highways for 706 
intercellular organelle transport. Science. 2004;303(5660):1007-10. 707 
98. Koyanagi M, Brandes RP, Haendeler J, Zeiher AM, Dimmeler S. Cell-to-cell connection 708 
of endothelial progenitor cells with cardiac myocytes by nanotubes: a novel mechanism for 709 
cell fate changes? Circ Res. 2005;96(10):1039-41. 710 
99. Lai RC, Tan SS, Yeo RW, Choo AB, Reiner AT, Su Y, et al. MSC secretes at least 3 EV 711 
types each with a unique permutation of membrane lipid, protein and RNA. J Extracell 712 
Vesicles. 2016;5:29828. 713 
100. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. 714 
J Cell Biol. 2013;200(4):373-83. 715 
101. van Niel G, Porto-Carreiro I, Simoes S, Raposo G. Exosomes: a common pathway for a 716 
specialized function. J Biochem. 2006;140(1):13-21. 717 
102. Tricarico C, Clancy J, D'Souza-Schorey C. Biology and biogenesis of shed microvesicles. 718 
Small GTPases. 2017;8(4):220-32. 719 
103. Monsel A, Zhu YG, Gennai S, Hao Q, Hu S, Rouby JJ, et al. Therapeutic Effects of Human 720 
Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice. Am J Respir Crit 721 
Care Med. 2015;192(3):324-36. 722 
104. Guescini M, Genedani S, Stocchi V, Agnati LF. Astrocytes and Glioblastoma cells 723 
release exosomes carrying mtDNA. J Neural Transm (Vienna). 2010;117(1):1-4. 724 
105. Guescini M, Guidolin D, Vallorani L, Casadei L, Gioacchini AM, Tibollo P, et al. C2C12 725 
myoblasts release micro-vesicles containing mtDNA and proteins involved in signal 726 
transduction. Exp Cell Res. 2010;316(12):1977-84. 727 
106. Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, et al. Mitochondrial transfer 728 
from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung 729 
injury. Nat Med. 2012;18(5):759-65. 730 
107. Eugenin EA, Gaskill PJ, Berman JW. Tunneling nanotubes (TNT): A potential 731 
mechanism for intercellular HIV trafficking. Commun Integr Biol. 2009;2(3):243-4. 732 
108. Mistry JJ, Marlein CR, Moore JA, Hellmich C, Wojtowicz EE, Smith JGW, et al. ROS-733 
mediated PI3K activation drives mitochondrial transfer from stromal cells to hematopoietic 734 
stem cells in response to infection. Proc Natl Acad Sci U S A. 2019;116(49):24610-9. 735 
109. Wada KI, Hosokawa K, Ito Y, Maeda M. Quantitative control of mitochondria transfer 736 
between live single cells using a microfluidic device. Biol Open. 2017;6(12):1960-5. 737 
110. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial 738 
DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104-7. 739 
111. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7. 740 
112. (NICE) TNIfHaCE. Daratumumab with bortezomib and dexamethasone for previously 741 
treated multiple myeloma. 2019. 742 
113. Excellence NIfHaC. Daratumumab monotherapy for treating relapsed and refractory 743 
multiple myeloma. 2018. 744 
  745 
TABLES 746 
TABLE 1: Mitochondrial transfer from the TME to cancer cells  747 
FIGURE LEGENDS 748 
Figure 1: Metabolism in melanoma. A) The smooth co-operation of OXPHOS and glycolysis in 749 
the two spatially distinct melanoma cell populations (melanoma cells in the centre that use 750 
glycolysis versus melanoma cells in periphery that use OXPHOS mainly for energy production) 751 
promotes melanoma initiation, growth and metastasis of melanoma through metabolic 752 
symbiosis, whereby the waste products from glycolysis are used to feed into the TCA cycle for 753 
OXPHOS in melanoma cells in the periphery. B) Mesenchymal stromal cells (MSCs) migrate 754 
from the bone marrow and liver towards the melanoma, where they are then manipulated 755 
by tumour cells to produce lactate and other macromolecules via glycolysis, for use by 756 
melanoma cells that mainly use OXPHOS in the peripheral part of the tumour (Reverse 757 
Warburg).  758 
 759 
Figure 2: Mechanisms of mtDNA transfer A) tunnelling nanotubules (TNTs), B) microvesicles 760 
and C) gap junctions, as well as other plausible mechanisms that require further research, 761 
such as D) cell fusion and E) direct mtDNA secretion into extracellular media.  762 
 
